Pharmaceuticals

APELOA

APELOA released FY2026 Q1 earnings on April 20 Pre-Market (BJT), actual revenue CNY 2.447 B, actual EPS CNY 0.2152 (forecast EPS CNY 0.19)

APELOA to Release FY2026 Q1 Earnings on April 21 Pre-Market (BJT), Forecast EPS CNY 0.19

APELOA released FY2025 Annual Earnings on March 19 After-Market (BJT), actual revenue CNY 9.784 B (forecast CNY 9.9 B), actual EPS CNY 0.7723 (forecast CNY 0.89)

APELOA released FY2025 Q4 earnings on March 19 After-Market (BJT), actual revenue CNY 2.02 B, actual EPS CNY 0.1658 (forecast EPS CNY 0.28)

APELOA to release FY2025 earnings report on March 20, 2026, After-Market BJT, with forecast revenue of CNY 9.9 B and EPS of CNY 0.89

APELOA released FY2025 Q3 earnings on October 21 After-Market (BJT), actual revenue CNY 2.319 B, actual EPS CNY 0.1194 (forecast EPS CNY 0.26)

APELOA released FY2025 9 Months Earnings on October 21 After-Market (BJT), actual revenue CNY 7.764 B, actual EPS CNY 0.6061

APELOA to release FY2025 Q3 earnings on October 22 After-Market BJT, forecast EPS CNY 0.26

APELOA released FY2025 Q2 earnings on August 19 During-Market (BJT), actual revenue CNY 2.714 B, actual EPS CNY 0.274 (forecast EPS CNY 0.32)

APELOA released FY2025 Semi-Annual earnings on August 19 During-Market (BJT), actual revenue CNY 5.444 B, actual EPS CNY 0.4861

APELOA FY2025 Semi-Annual Earning Release on August 20, 2025 (BJT)

Puyao Pharmaceutical Maintains Steady Order Trend in H2

Puropharm's ESG Rating Upgraded to A

Puyao Pharmaceutical's Subsidiary Receives Certificate for Cefixime Capsules

Puyao Pharmaceutical's subsidiary obtains approval for the raw material of Tenofovir

Puyao Pharmaceutical Adds Influenza Concept and Releases Q1 2025 Earnings Report

Zhejiang Puluoyuan Home Pharmaceutical Receives Approval for Desvenlafaxine Succinate API

NMPA Conducts On-site Inspection for Prol Pharma's Subsidiary

Puropharma Planning Stock Repurchase and Business Growth

Prolpharma Group Net Profit Grew by 1.98% in Q1 2025

603538

000739

Chinese suppliers of active pharmaceutical ingredients (APIs) are increasing prices due to higher raw material costs from the Middle East conflict. Vitamin A prices surged 93% to CNY116.50 per kilogram, while Vitamin E prices doubled. Companies like Apeloa Pharmaceutical and Menovo Pharmaceutical are adjusting prices to offset increased costs, with expectations of improved earnings as supply growth is constrained. The API market is tightening, allowing producers to pass on costs to buyers, which may lead to further price increases in response to rising demand for chronic disease drugs.

Yicai

Menovo

Chinese API Suppliers Pass On Higher Raw Material Costs Arising From Mideast War

510660

159992

Innovative drug concept stocks continue to be strong, with Menovo hitting a 3-day consecutive limit up, followed by Fushine, BHC, Kingchem, APELOA, and WuXi AppTec

Wallstreetcn

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

ICBCCS SSE STAR Biology and Medicine ETF

Fushine

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

WuXi AppTec

Kingchem

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE STAR Biology and Medicine ETF

According to the Zhitong Finance APP, APELOA announced that as of October 31, 2025, the company has repurchased a total of 10.06 million shares through centralized bidding, accounting for 0.87% of the company's current total share capital, with a total transaction amount of 144 million yuan (excluding transaction fees)

Zhitong

APELOA has repurchased a total of 10.06 million shares at a cost of 144 million yuan

APELOA's subsidiary, Zhejiang Puluo Kangyu Pharmaceutical Co., Ltd., has obtained the drug registration certificate for L-Carnitine Injection issued by the National Medical Products Administration. This drug is suitable for complications in patients with chronic renal failure, with an expected market size of 103 million units and sales amounting to 965 million yuan in China's hospital market in 2024. To date, the cumulative research and development expenses amount to 3.7629 million yuan

APELOA's subsidiary has obtained the drug registration certificate for L-carnitine injection

According to the Zhitong Finance APP, APELOA released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 7.764 billion yuan, a year-on-year decrease of 16.43%. The net profit attributable to shareholders of the listed company was 700 million yuan, a year-on-year decrease of 19.48%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 647 million yuan, a year-on-year decrease of 22.14%. The basic earnings per share were 0.6063 yuan

APELOA released its performance for the first three quarters, with a net profit attributable to the parent company of 700 million yuan, a decrease of 19.48%

603456

603127

06127

688602

688293

CRO concept stocks fluctuated upward, Jiuzhou Pharma hit the daily limit, APELOA rose over 5%, JOINN, Chemspec, OPM, and Haoyuan Pharma followed suit

Jiuzhou Pharma

JOINN

Chemspec

CRO concept stocks fluctuate and rise, Jiuzhou Pharma hits the limit up

APELOA stated on the interactive platform that the company's CDMO business has performed better than the API business. On one hand, the API business is at the bottom of the industry cycle, facing year-on-year performance pressure; on the other hand, the CDMO business is gradually entering a harvest period, and it is expected to lead the company's performance into a new growth stage

APELOA: CDMO business is gradually entering a harvest period and is expected to lead the company's performance into a new growth stage

APELOA stated on the interactive platform that the company has established long-term and close cooperative relationships with several globally leading pet pharmaceutical companies. As of now, the company has 49 pet pharmaceutical projects, with both the number of projects and sales revenue maintaining a continuous growth trend

APELOA: As of now, the company has 49 pet medicine projects

APELOA stated on the interactive platform that the Phase III clinical trial for its semaglutide project (including indications for weight loss and blood sugar reduction) has completed all patient enrollment and is currently in the follow-up phase of administration

APELOA: The Phase III clinical trial of the Semaglutide project has completed all enrollments

APELOA(000739.SZ)